Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review”

Przemysław Holko ()
Additional contact information
Przemysław Holko: Pharmacoeconomic Research Center

PharmacoEconomics - Open, 2017, vol. 1, issue 1, No 7, 69-70

Keywords: Inflammatory Bowel Disease; Infliximab; Economic Evaluation; Ustekinumab; Price Impact (search for similar items in EconPapers)
Date: 2017
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s41669-016-0008-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:1:y:2017:i:1:d:10.1007_s41669-016-0008-x

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-016-0008-x

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().